Clinical Trial Details

< Previous Trial     Next Trial >
Study ID VB4-845-01-IIIA
Investigator
Wendy Cuthbert,   Viventia Biotech Inc.
Title Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer
Conditions Advanced Squamous Cell Carcinoma of the Head and Neck
Carcinoma, Squamous Cell
Neoplasms, Squamous Cell
Head and Neck Neoplasms
Mouth Neoplasms
Head and Neck Cancer
Interventions Drug: Proxinium
Phase Phase 2/Phase 3
Purpose The purpose of this study is to compare the safety and efficacy of Proxinium plus best supportive care with best supportive care only for patients with squamous cell head and neck cancer.
Eligibility Ages Eligible: 18 Years
Genders Eligible:  Both
Accepts Healthy Volunteers:  No
Inclusion Criteria: Disease Characteristics
  • The patient must be 18 years of age or older.
  • The patient must have squamous cell carcinoma of the head and neck.
  • The squamous cell carcinoma must be Ep-CAM positive.
  • ECOG performance status of 0, 1, 2 or 3.
  • 12 week life expectancy Prior/Concurrent Therapy
  • The patient must have received therapy for their primary disease (eg, surgery and/or radiotherapy, chemo-radiotherapy or chemotherapy).
  • The patient must have been diagnosed with persistent or recurrent disease or a second primary tumour.
  • The patient's disease must be refractory.
  • There must be at least 2 weeks between the last dose of chemotherapy or radiotherapy and receiving study drug or 4 weeks between the last dose of an experimental drug and receiving study drug. Patient Characteristics
  • The patient must have adequate hepatic function [alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × upper limit of normal (ULN) and bilirubin level ≤1.5 × ULN].
  • The patient must have adequate renal function (serum creatinine < 1.5 × ULN).
  • The patient must have the following hematological values: granulocytes ≥1500/μL, platelets ≥75 000/μL and hemoglobin >8 g/dL.
  • The patient must have prothrombin time and partial thromboplastin time within normal limits. Other • Women of childbearing potential and male patients must agree to use a highly effective contraceptive method. Exclusion Criteria:
    • The patient has clinically significant distant metastases.
    • The patient is eligible to have surgical resection or radiotherapy, chemo-radiotherapy or chemotherapy.
    • The patient has a nasopharyngeal tumour.
    • The patient has AIDS, hepatitis C or hepatitis B.
    • The patient has clinically significant renal or hepatic disease.
    • Tumors are prone to bleeding.
    • The patient is pregnant or lactating.
    • The patient requires 'blood thinning' medications and can not safely discontinue the medication.
    • The patient is currently enrolled in another clinical trial.
  • Study Location
    Contact

    Information objtained from ClinicalTrials.gov, on 9/1/2014. For additional information about this and other clinical trials, visit http://clinicaltrials.gov.
    Please refer to this study by its ClinicalTrials.gov identifier: NCT00412776


    Back to Search Results